Innovative Trials enters partnership to complete trial recruitment and retention

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/PeopleImages)
(Image: Getty/PeopleImages)

Related tags: trial recruitment, Clinical trial, Clinical research, Pharmaceutical companies, Site selection, Service

Innovative Trials will work with an undisclosed global pharmaceutical company to speed up patient recruitment for clinical trials using its proactive site optimization service.

The UK-based clinical trial recruitment business was selected by an undisclosed company to help recruit and retain patients for trials related to breast cancer, schizophrenia, and Crohn’s disease.

Kate Shaw, CEO of Innovative Trials, said in a statement that applying its recruitment strategies through this partnership is a “fantastic achievement.”

Innovative Trials implemented its proactive patient recruitment and retention strategies, including its site optimization service. The service uses local language patient recruitment coaching services to work with sites to develop and implement patient recruitment strategies.

Shaw told us that the service is currently being run in 50 countries and Innovative Trials’ site optimization service has been completed more than 25,500 times.

“The majority of clinical trials do not complete patient recruitment on time, which can cost pharmaceutical companies a lot of money and delay treatments getting to patients,”​ said Shaw.

Innovative Trials also provides global site recruitment materials to assist in clinical trial management. These materials ensure that the patients receive ethically approved, educational materials to enable patients to make informed decisions.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars